CHICAGO (GenomeWeb) – The Multiple Myeloma Research Foundation will invest $5 million over the next three years in an effort to boost precision medicine’s profile among clinicians and patients.
The Norwalk, Connecticut-based organization today announced the launch of the MMRF Answer Fund, which seeks to support the development of better ways to identify and treat patients at high risk for multiple myeloma. To this end, the MMRF today issued a request for research projects that rely on data from the ongoing MMRF CoMMpass study, to be paid for by the new fund.
The MMRF Answer Fund will also crowdsource questions from patients, clinicians, and researchers in an effort to pinpoint the “most pressing challenges they face in maximizing clinical outcomes for every patient in this era of precision medicine,” the organization said. In the fall, the MMRF will issue another request for applications to find researchers to answer these questions.
“The MMRF CoMMpass Study gives us an incredible quantity of world-class data from which we can glean insights to solve the most urgent questions facing myeloma patients,” MMRF President and CEO Paul Giusti said in a statement. “By getting to the heart of these questions, we will accelerate precision medicine